)
)
)
Regerna Therapeutics
Muscle repair and regeneration company built on deep understanding of mRNA-binding proteins and their impact on longevity and healthy aging. Lead clinical candidate, AUF1, known master muscle regulator with potential to revolutionize treatment of age-related, traumatic and genetic muscle disorders.
Supplementing AUF1 benefits all components necessary for full restoration of active, functional muscle - including significant, measurable re-innervation, increase in blood vessels and muscle stem cells, and improvement of mitochondrial function.
Utilizing LNP delivery targets post-injury and surgical disuse atrophy with focused clinical development and product evolution path. Future indications include aging associated atrophy, degenerative and neuromuscular diseases, muscle loss from GLP-1 agonist therapies, and volumetric muscle loss. Utilizing AAV delivery to address segments of muscular dystrophies that are not adequately addressed.
Clinical entry expected within two years.
Address
New YorkNew York
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)